J. Maffrand

J. Maffrand, M. Rinaldi-Carmona, G. Le Fur, 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Functional assessment of β adrenoceptor subtypes in human colonic circular and longitudinal (taenia coli) smooth muscle

J. Maffrand, G. Le Fur, T. Croci, 2000, Gut.

A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1

P. Casellas, J. Maffrand, M. Rinaldi-Carmona, 1997, The Journal of Biological Chemistry.

Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity.

J. Herbert, J. Maffrand, 1991, Biochimica et biophysica acta.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.

P. Soubrié, D. Gully, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

Direct thrombin inhibitors.

J. Maffrand, 1992, Nouvelle revue francaise d'hematologie.

The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.

P. Casellas, J. Maffrand, B. Bourrie, 1999, Proceedings of the National Academy of Sciences of the United States of America.

ADP Receptor Induced Activation of Guanine Nucleotide Binding Proteins in Rat Platelet Membranes– An Effect Selectively Blocked by the Thienopyridine Clopidogrel

K. Jakobs, J. Maffrand, P. Ohlmann, 1992, Thrombosis and Haemostasis.

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

P. Soubrié, J. Maffrand, M. Arnone, 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

Antiplatelet Effects of the Addition of Acetylsalicylic Acid 40 Mg Daily to Ticlopidine in Human Healthy Volunteers

J. Maffrand, M. Samama, T. Lecompte, 1997 .

Comparative Arterial Antithrombotic Activity of Clopidogrel and Acetyl Salicylic Acid in the Pig

C. Samama, M. Bonneau, J. Maffrand, 1992, Thrombosis and Haemostasis.

Importance of platelets in experimental venous thrombosis in the rat.

J. Herbert, J. Maffrand, A. Bernat, 1992, Blood.

Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.

J. Herbert, J. Maffrand, A. Bernat, 1992, Journal of lipid mediators.

The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat.

J. Maffrand, A. Bernat, J. Gordon, 1988, Thrombosis research.

Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

J. Herbert, J. Maffrand, J P Maffrand, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species.

C. Legrand, F. Incardona, J. Maffrand, 1995, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

B. Scatton, J. Maffrand, E. Naline, 2004, Journal of Pharmacology and Experimental Therapeutics.

SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.

J. Simiand, P. Soubrié, R. Boigegrain, 1999, The Journal of pharmacology and experimental therapeutics.

New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.

J. Herbert, J. Maffrand, P. Savi, 1997, Journal of medicinal chemistry.

The total synthesis of (+)-ryanodol. Part III. Preparation of (+)-anhydroryanodol from a key pentacyclic intermediate

A. Bélanger, C. Liao, J. Maffrand, 1990 .

The total synthesis of (+)-ryanodol. Part I. General strategy and search for a convenient diene for the construction of a key tricyclic intermediate

A. Bélanger, C. Liao, J. Maffrand, 1990 .

The total synthesis of (+)-ryanodol. Part II. Model studies for rings B and C of (+)-anhydroryanodol. Preparation of a key pentacyclic intermediate

A. Bélanger, C. Liao, J. Maffrand, 1990 .

The total synthesis of (+)-ryanodol. Part IV. Preparation of (+)-ryanodol from (+)-anhydroryanodol

A. Bélanger, C. Liao, J. Maffrand, 1990 .

Total synthesis of ryanodol

A. Bélanger, C. Liao, J. Maffrand, 1979 .

Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor

G. Fur, J. Herbert, J. Maffrand, 1992 .

Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C.

J. Herbert, J. Augereau, J. Gleye, 1991, Journal of natural products.

Role of tachykinins in castor oil diarrhoea in rats

G. Fur, J. Maffrand, T. Croci, 1997, British journal of pharmacology.

Structure and stereochemistry of the active metabolite of clopidogrel.

M. Maftouh, J. Herbert, J. Maffrand, 2002, Drug metabolism and disposition: the biological fate of chemicals.

IN VITRO METABOLISM OF FERROQUINE (SSR97193) IN ANIMAL AND HUMAN HEPATIC MODELS AND ANTIMALARIAL ACTIVITY OF MAJOR METABOLITES ON PLASMODIUM FALCIPARUM

Christophe Biot, Laurent Fraisse, C. Biot, 2006, Drug Metabolism and Disposition.

An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function.

P. Nurden, J. Herbert, J. Maffrand, 1995, The Journal of clinical investigation.

Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin.

C. Roitsch, J. Maffrand, E. Degryse, 1989, Protein engineering.

The 100-kDa Neurotensin Receptor Is gp95/Sortilin, A Non-G-Protein-coupled Receptor*

M. Kaghad, P. Ferrara, D. Caput, 1998, The Journal of Biological Chemistry.

Characterization of specific binding sites for [3H]-staurosporine on various protein kinases.

J. Herbert, J. Maffrand, J P Maffrand, 1990, Biochemical and biophysical research communications.

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

G. Griebel, J. Simiand, P. Soubrié, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacokinetics of 125I-pentosan polysulfate in the rabbit.

G. Houin, J. Maffrand, B. Boneu, 1987, Thrombosis research.

Biochemical and pharmacological properties of clopidogrel : a new ADP receptor antagonist

J. Herbert, J. Maffrand, P. Savi, 1999 .

SR 121787, a New Orally Active Fibrinogen Receptor Antagonist

J. Herbert, J. Maffrand, P. Hoffmann, 1998, Thrombosis and Haemostasis.

Effect of Various Antiplatelet Agents on Acute Arterial Thrombosis in the Rat

J. Herbert, J. Maffrand, A. Bernat, 1993, Thrombosis and Haemostasis.

Antithrombotic and Bleeding Effects of a New Synthetic Direct Thrombin Inhibitor and of Standard Heparin in the Rabbit

J. Maffrand, B. Boneu, A. Bernat, 1987, Thrombosis and Haemostasis.

Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds.

J. Herbert, J. Maffrand, J. Gordon, 1987, Thrombosis research.

Circannual variations of the bleeding time in the rat.

J. Herbert, J. Maffrand, A. Bernat, 1993, Chronobiology international.

Purification and Characterization of the Human SR 31747A-binding Protein

S. Galiègue, P. Casellas, P. Ferrara, 1997, The Journal of Biological Chemistry.

Characterization of extracellular binding sites for [3H]-staurosporine on capillary endothelial cells.

J. Herbert, J. Maffrand, I. Daviet, 1991, Cell biology international reports.

Tumor cell adherence to cultured capillary endothelial cells is promoted by activators of protein kinase C.

J. Herbert, J. Maffrand, 1991, Biochemical pharmacology.

Syntheses of Nα-(β-naphthylsulfonylaminoglycyl)-argininamides as potential selective synthetic thrombin inhibitors

J. Maffrand, D. Frehel, G. Etemad-moghadam, 1988 .

Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats

J. Maffrand, G. Le Fur, T. Croci, 1997, British journal of pharmacology.

Identification and Biological Activity of the Active Metabolite of Clopidogrel

J. Herbert, J. Maffrand, M. Pascal, 2000, Thrombosis and Haemostasis.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

J. Herbert, J. Maffrand, P. Savi, 1994, Thrombosis and Haemostasis.

A simple experimental model of thrombolysis in the rat: Effect of urokinase and streptokinase

J. Maffrand, A. Bernat, E. Vallée, 1986 .

A nonpeptide vasopressin V1a receptor antagonist, SR 49059, does not prevent cisplatin‐induced emesis in piglets

L. Grélot, J. Maffrand, C. Serradeil-Le Gal, 2001, Fundamental & clinical pharmacology.

Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel.

J. Herbert, J. Maffrand, P. Savi, 1992, Biochemical pharmacology.

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

P. Soubrié, D. Gully, R. Boigegrain, 1997, The Journal of pharmacology and experimental therapeutics.

ADP Plays a Key Role in Thrombogenesis in Rats

J. Maffrand, J. Cazenave, A. Bernat, 1988, Thrombosis and Haemostasis.

Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat platelets.

J. Maffrand, M. Simon, G. Defreyn, 1988, Biochemical pharmacology.

Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP.

J. Maffrand, M. Simon, G. Defreyn, 1987, Thrombosis research.

THE THIENOPYRIDINE PCR 4099 INHIBITS THE ADP AGGREGATION PATHWAY OF HUMAN PLATELETS BY INTERFERING WITH THE BINDING OF FIBRINOGEN TO THE GLYCOPROTEIN IIb-IIIa COMPLEX

J. Maffrand, C. Gachet, J. Cazenave, 1987, Thrombosis and Haemostasis.

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related

G. Griebel, J. Simiand, P. Soubrié, 2002, The Journal of pharmacology and experimental therapeutics.

3-thiazol-2-amine Hydrochloride ( SSR 125543 A ) , a Potent and Selective Corticotrophin-Releasing Factor 1 Receptor Antagonist . II . Characterization in Rodent Models of Stress-Related Disorders

G. Griebel, J. Simiand, P. Soubrié, 2002 .

Behavior of confluent endothelial cells after irradiation. Modulation of wound repair by heparin and acidic fibroblast growth factor

J. Maffrand, J. Cazenave, A. Beretz, 1990, Biology of the cell.

Selection of a trioxaquine as an antimalarial drug candidate

B. Mordmüller, P. Kremsner, J. Maffrand, 2008, Proceedings of the National Academy of Sciences.

Characterization and localization of leptin receptors in the rat kidney

J. Maffrand, G. Le Fur, C. Serradeil-Le Gal, 1997, FEBS letters.

Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.

J. Herbert, J. Maffrand, P. Savi, 1994, The Journal of pharmacology and experimental therapeutics.

The Total Synthesis of (+)-Ryanodol. Part 1. General Strategy and Search for a Convenient Diene for the Construction of a Key Tricyclic Intermediate.

A. Bélanger, C. Liao, J. Maffrand, 1990 .

An Efficient Synthesis of Azathia Analogs of Platelet-Activating Factor

J. Maffrand, G. Bertrand, B. Garrigues, 1984 .

Experimental and clinical pharmacology of pentosan polysulfate.

J. Herbert, J. Maffrand, P. Savi, 1991, Seminars in thrombosis and hemostasis.

The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

P. Soubrié, F. Oury-Donat, J. Maffrand, 2003, Molecular pharmacology.

Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis.

P. Cobbold, J. Hanoune, S. Lotersztajn, 1991, The Journal of clinical investigation.

Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor.

J. Herbert, J. Maffrand, G. Le Fur, 1992, The Journal of pharmacology and experimental therapeutics.

In vitro functional evidence of different neurotensin‐receptors modulating the motor response of human colonic muscle strips

P. Chalon, P. Ferrara, J. Maffrand, 1999, British journal of pharmacology.

Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.

P. Soubrié, D. Gully, R. Boigegrain, 1997, The Journal of pharmacology and experimental therapeutics.

Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

P Ferrara, P. Soubrié, P. Casellas, 1998, European journal of pharmacology.

Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells.

D. Gully, J. Maffrand, C. Lair, 1997, Biochemical and biophysical research communications.